News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PhaseRx (PZRX) Reports Second Quarter 2017 Financial Results And Provides Corporate Update



8/10/2017 1:47:08 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
SEATTLE, Aug. 10, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today reported financial results for the second quarter ended June 30, 2017 and provided an update on its corporate activities.

"PhaseRx continued to make solid progress in the second quarter of 2017 with the receipt of orphan drug designation for PRX-OTC from the European Medicines Agency," said Robert W. Overell, Ph.D., president and chief executive officer of PhaseRx.

Read at PR Newswire


comments powered by Disqus
PhaseRx
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES